Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme Inhibition01:30

Enzyme Inhibition

89.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
89.9K
Feedback Inhibition00:46

Feedback Inhibition

56.6K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
56.6K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

239
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
239
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

10.8K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.8K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

2.4K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.4K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

460
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
460

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Investigative reporting on factor VIII whereabouts.

Blood advances·2026
Same author

Corrigendum to 'Lack of factor VIII detection in humans and dogs with an intron 22 inversion challenges hypothesis regarding inhibitor risk' [Journal of Thrombosis and Haemostasis. Volume 22, Issue 12, December 2024, Pages 3415-3430].

Journal of thrombosis and haemostasis : JTH·2026
Same author

von Willebrand factor dynamics in trauma managed with extracorporeal life support.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.

Journal of thrombosis and haemostasis : JTH·2026
Same author

T cells from individuals with and without hemophilia A respond to the same epitopes in factor VIII.

Journal of thrombosis and haemostasis : JTH·2025
Same author

[A new role for antibodies in deep venous thrombosis].

Medecine sciences : M/S·2025
Same journal

Clinical Factors for Predicting Synovial Hypertrophy in Early Haemophilic Arthropathy on Prophylaxis: A Cross-Sectional Study of Patient- and Joint-Level Analyses Using Musculoskeletal Ultrasound.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Utilisation and Perceived Value of Genetic Counsellors Within US Haemophilia Treatment Centres.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Correction to "Reference Values for the Haemophilia Joint Health Score in Patients With Severe Haemophilia Derived From the Canadian Bleeding Disorder Registry".

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Perceived Barriers to Healthcare Access Among Paediatric Patients With Haemophilia in Cambodia: A Cross-Sectional Survey.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same journal

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH-AHA-EMI Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
See all related articles

Related Experiment Video

Updated: Dec 16, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K

Inhibitors-Recent insights.

Kathleen P Pratt1, Valder R Arruda2,3, Sébastien Lacroix-Desmazes4

  • 1Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|July 2, 2020
PubMed
Summary
This summary is machine-generated.

Developing inhibitors to factor VIII (FVIII) complicates haemophilia A (HA) treatment. This review explores immune responses and proposes that active peripheral immune tolerance, not ignorance, explains why some HA patients tolerate FVIII therapy.

Keywords:
FVIII inhibitorsfactor VIIIgene therapyhaemophilia Aimmune toleranceprotein immunogenicity

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

Related Experiment Videos

Last Updated: Dec 16, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.4K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

Area of Science:

  • Immunology
  • Hematology
  • Gene Therapy

Background:

  • Inhibitory antibodies to factor VIII (FVIII) are a major complication in treating haemophilia A (HA).
  • The mechanisms underlying inhibitor development in some HA patients but not others remain unclear.
  • Understanding anti-FVIII immune responses is crucial for effective HA management.

Purpose of the Study:

  • To review current understanding of anti-FVIII immune responses in HA patients.
  • To discuss the roles of T cells (effector and regulatory) in anti-FVIII immunity.
  • To explore the interplay between FVIII and the immune system in factor and gene therapies.

Main Methods:

  • Review of existing literature on anti-FVIII immune responses.
  • Analysis of the roles of T cells in immune tolerance and inhibitor development.
  • Comparison of haemophilia A (FVIII) and haemophilia B (factor IX) therapies.

Main Results:

  • Proposes that active peripheral immune tolerance underlies FVIII acceptance in both HA and non-HA individuals.
  • Suggests that inhibitor-negative HA patients have actively tolerized to exogenous FVIII.
  • Identifies potential strategies for inducing peripheral immune tolerance in HA patients.

Conclusions:

  • Immune tolerance, not immune ignorance, is key to understanding FVIII acceptance in HA.
  • Targeted immune stimulation strategies, including intensive FVIII therapy or gene therapy, may induce tolerance.
  • Further research into immune tolerance mechanisms can improve HA treatment outcomes.